Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Xianxiang Medical Technology
Shanghai, Shanghai Shi, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Xianxiang Medical Technology is actively advancing multiple small molecule and antibody-based programs in oncology, neurology, autoimmune diseases, and anti-infective treatments. The company has presented Phase 1 clinical data on a PRMT5 inhibitor (SCR-6920) in advanced tumors, showing no dose-limiting toxicities in 25 patients and dose-dependent plasma biomarker response. Several trispecific and ADC programs are also in early clinical phases.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeAntibody-drug conjugateTrispecific T-cell engager
- Industry
- Biotech
Beyond the preview
Go deeper on Shanghai Xianxiang Medical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Xianxiang Medical Technology.